Loading…
Loading…
See exactly how VIOV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VIOV and 80,000+ other tickers.
Vanguard Admiral Funds - Vanguard S&P Small-Cap 600 Value ETF is an exchange traded fund launched and managed by The Vanguard Group, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across diversified sectors. The fund invests in value stocks of small-cap companies. It seeks to track the performance of the S&P SmallCap 600 Value Index, by using full replication technique. Vanguard Admiral Funds - Vanguard S&P Small-Cap 600 Value ETF was formed on September 7, 2010 and is domiciled in the United States.
Launched on September 9, 2010, the Vanguard S&P Small-Cap 600 Value Index Fund ETF Shares (VIOV) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Value segment of the US equity market.
Small-cap equities are winning out against their large-cap counterparts in a classic David versus Goliath ETF battle. After years of mega-cap technology dominance, small-cap equities have delivered investors a historic first half of 2026.
Designed to provide broad exposure to the Small Cap Value segment of the US equity market, the Vanguard S&P Small-Cap 600 Value Index Fund ETF Shares (VIOV) is a passively managed exchange traded fund launched on September 9, 2010.
Launched on September 9, 2010, the Vanguard S&P Small-Cap 600 Value Index Fund ETF Shares (VIOV) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Value segment of the US equity market.
Vanguard S&P Small-Cap 600 Value Index Fund ETF (VIOV) has recently outperformed peer small-cap ETFs and is rated a cautious buy. VIOV's built-in profitability screen filters out loss-making companies, enhancing quality and supporting outperformance versus the Russell 2000. The fund is well positioned in financials and healthcare, sectors expected to benefit from macro tailwinds and potential rate cuts in 2026.